Researchers have made a discovery related to the treatment of glioblastoma, involving the use of peptide-drug conjugates to repolarize glioblastoma-associated macrophages. This approach appears to be aimed at resensitizing glioblastoma to chemo-immunotherapy. The method of delivery involves a targeted system that responds to cathepsin B, although the specifics of the mechanism and application are still being explored.